|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.66 USD | +0.16% |
|
-5.51% | -5.41% |
| 03-12 | Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 | CI |
| 03-12 | Halozyme Therapeutics Appoints David Ramsay as Interim CFO | MT |
| Capitalization | 7.51B 6.57B 5.93B 5.68B 10.32B 695B 10.73B 70.88B 28.09B 332B 28.19B 27.6B 1,199B | P/E ratio 2026 * |
7.3x | P/E ratio 2027 * | 7.22x |
|---|---|---|---|---|---|
| Enterprise value | 8.53B 7.45B 6.73B 6.44B 11.72B 789B 12.18B 80.45B 31.88B 377B 32B 31.32B 1,361B | EV / Sales 2026 * |
4.86x | EV / Sales 2027 * | 3.7x |
| Free-Float |
98.92% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | +0.16% | ||
| 1 week | -5.51% | ||
| Current month | -8.44% | ||
| 1 month | -19.86% | ||
| 3 months | +2.33% | ||
| 6 months | -17.22% | ||
| Current year | -5.41% |
| 1 week | 63.22 |  | 68.4 |
| 1 month | 63.22 | | 81.51 |
| Current year | 63.22 | | 82.22 |
| 1 year | 47.5 | | 82.22 |
| 3 years | 29.85 | | 82.22 |
| 5 years | 29.85 | | 82.22 |
| 10 years | 7.52 | | 82.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 2014-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 43 | 2022-02-01 |
Chris Wahl
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 2013-03-27 |
Helen Torley
BRD | Director/Board Member | 63 | 2014-01-05 |
| Chairman | 61 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | -5.51% | +4.26% | +48.36% | 7.5B | |
| -1.51% | -2.13% | -19.79% | -36.53% | 54.85B | |
| +1.22% | +3.53% | +6.98% | -17.98% | 7.57B | |
| -0.61% | -4.96% | -6.95% | +59.54% | 5.17B | |
| -0.60% | 0.00% | -17.52% | +104.44% | 4.98B | |
| -1.09% | -7.35% | +60.12% | +42.64% | 2.91B | |
| -0.69% | -1.73% | -12.45% | -21.49% | 2.67B | |
| -1.06% | -0.10% | +44.12% | +49.37% | 2.57B | |
| +2.63% | -0.32% | +356.78% | +526.63% | 2.48B | |
| -0.09% | +1.20% | -3.78% | +6.93% | 2.14B | |
| Average | -0.16% | -0.42% | +41.18% | +76.19% | 9.28B | |
| Weighted average by Cap. | -0.86% | -1.22% | +0.07% | +6.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.76B 1.53B 1.39B 1.33B 2.41B 162B 2.51B 16.56B 6.56B 77.59B 6.59B 6.45B 280B | 1.98B 1.73B 1.56B 1.5B 2.72B 183B 2.83B 18.69B 7.41B 87.53B 7.43B 7.28B 316B |
| Net income | 992M 867M 783M 749M 1.36B 91.76B 1.42B 9.36B 3.71B 43.84B 3.72B 3.64B 158B | 1.05B 914M 826M 790M 1.44B 96.71B 1.49B 9.86B 3.91B 46.2B 3.92B 3.84B 167B |
| Net Debt | 1.01B 887M 801M 767M 1.39B 93.87B 1.45B 9.57B 3.79B 44.85B 3.81B 3.73B 162B | -176M -154M -139M -133M -241M -16.24B -251M -1.66B -657M -7.76B -659M -645M -28.03B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-13 | 63.66 $ | +0.16% | 1,134,140 |
| 26-03-12 | 63.56 $ | -4.39% | 2,152,599 |
| 26-03-11 | 66.48 $ | -1.96% | 1,544,621 |
| 26-03-10 | 67.81 $ | -0.48% | 1,353,731 |
| 26-03-09 | 68.14 $ | +1.14% | 1,610,804 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition